|
|
Post by mnholdem on Jul 29, 2018 10:35:32 GMT -5
Rose also wears a finance department hat. She held the fort in the interim between Pfeffer’s departure and the hiring of CFO Steve Binder, who she now reports to.
|
|
|
|
Post by mnholdem on Jul 28, 2018 20:33:55 GMT -5
Check their website. Read about some of the deals then judge for yourself.  |
|
|
|
Post by mnholdem on Jul 28, 2018 18:16:18 GMT -5
Banks is also the founder of Bourne Partners, a leading financial services firm. For over 20 years, Bourne Partners has transacted with nearly all major pharmaceutical and specialty pharmaceuticals companies around the world, including Banks’ initial investment in King Pharmaceuticals in the late 1990’s. This investment introduced Banks to the pharmaceutical world and jumpstarted his interest in the healthcare sector. Since then, Bourne Partners has been party to more than $10 billion of transactions in pharmaceutical (“pharma”), pharma services and consumer health, and Banks has invested in more than 200 private companies / assets since 2000. Most recently the Bourne Team and other partners co-founded Covis Pharma S.à.r.l. in 2011, successfully helping build and eventually divest the majority of assets in 2015 for $1.2 billion. In late 2015 the firm established Phoenix Therapeutics, Inc., a joint venture with The Carlyle Group. This makes me wonder if there may be non-dilutive financing over the horizon since there may be a vested interest in this Tanner deal becoming lucrative by helping MannKind fund its business plan. |
|
|
|
Post by mnholdem on Jul 28, 2018 15:41:45 GMT -5
It seems to me that CEO mentioned deals being worked on for which Afrezza would reach 50% of the world's diabetes population. I don't think Tanner is related to that other term sheet. I still think that it's about China and has been delayed because of the agreement MannKind has with Amphastar, granting them the first right to sales in China and to match any partnership offer for that region. Combined, India and China account for more than half of the global diabetes population. I think the Tanner deal is something else entirely.  |
|
|
|
Post by mnholdem on Jul 28, 2018 15:25:51 GMT -5
|
|
|
|
Post by mnholdem on Jul 28, 2018 11:21:47 GMT -5
Excellent discussion here and on point for the thread title “Reality of the Situation”.
What is “reality”? Frankly, reality varies from person to person depending on his/her perspective and experience and I find it to be very interesting reading. Thank you all!
|
|
|
|
Post by mnholdem on Jul 28, 2018 11:02:36 GMT -5
[Original link to article was incorrect. See new link (below).]
A fair piece, IMO.
|
|
|
|
Post by mnholdem on Jul 27, 2018 16:42:43 GMT -5
I have not seen "exclusive" anywhere. So this may be just another "distribution avenue". It all counts though. It may make logistics better and easier to sales forces and/or medics around the world. I am optimistic that the next corp meeting will provide details. agree with your observation. Here are a few of my observations on this: a. this distribution arrangement probably is not an exclusive distribution arrangement, as wmdhunt noted above. Note the language "The agreement names Tanner as a distributor of Afrezza® outside of the United States in regions the product is not yet registered." b. Further to the observation under item a. above, I would assume this arrangement is in addition to whatever partnership/ self-filing that Mannkind is working on (Europe, Canada, Mexico, China, Middle East), etc., as noted by Mike in previous conference calls/presentations. Matt’s post on this probably is what the two parties are thinking of (i.e., where Mannkind has not signed a distribution agreement or filed for approval itself, Tanner Pharmacy will have the rights to distribute Afrezza to the customers there). c. Tanner Pharmacy/Bourne Partner probably is not as niche or small as some would think. See a few relevant reports below. 1. The Carlyle Group and Bourne Partners Form Phoenix Therapeutics to Build Global Pharma Company NEW YORK, NY and CHARLOTTE, NC – Global alternative asset manager The Carlyle Group (NASDAQ: CG) announced today that it has formed a joint venture with Bourne Partners, a healthcare-focused investor, operator and investment banking firm, to build a global pharmaceutical platform. This new venture, known as Phoenix Therapeutics, will be owned by Carlyle Partners VI, a $13 billion U.S. buyout fund, with a minority investment from Bourne Partners. Leveraging the financial resources and experience of Carlyle and Bourne, Phoenix Therapeutics will look to operate a pharmaceutical platform built through acquisitions. Phoenix Therapeutics will consider a range of acquisitions, including product and asset acquisitions, corporate acquisitions and carve-outs. www.carlyle.com/media-room/news-release-archive/carlyle-group-and-bourne-partners-form-phoenix-therapeutics-build Bourne Partners Global Healthcare Summit in Charlotte NC on Oct 2 is being promoted by Tanner. www.tannerpharma.com/events/ |
|
|
|
Post by mnholdem on Jul 27, 2018 16:12:12 GMT -5
Even though MNKD pps is down -7.6% over the last three months and -43.0% over the last six months, the he stock price is up +20.5% over the last year at this date.
Price volatility is way down as well as MNKD appears to be in a holding pattern.
Or 78% off of the October high of the year. It figures that you grab the October spike to throw some water on a fire. One year comparisons are generally used by analysts and I meant to point out that there are some of us who don’t get rattled by daily swings in stock prices. Did that bother you or something? Do you expect long investors to be jumping off skyscrapers or something? |
|
|
|
Post by mnholdem on Jul 27, 2018 11:54:11 GMT -5
|
|
|
|
Post by mnholdem on Jul 27, 2018 7:00:47 GMT -5
Even though MNKD pps is down -7.6% over the last three months and -43.0% over the last six months, the he stock price is up +20.5% over the last year at this date.
Price volatility is way down as well as MNKD appears to be in a holding pattern.
|
|
|
|
Post by mnholdem on Jul 25, 2018 12:25:50 GMT -5
MannKind has contact information at their website.
|
|
|
|
Post by mnholdem on Jul 25, 2018 12:24:11 GMT -5
I don’t recall ever seeing any drug billboard ever. Just HelpLine advertisements for drug abuse. There has to be a reason why drugs cannot be advertised this way. I would guess that the FDA does not allow it because there wouldn’t be time to read the label warnings.
|
|
|
|
Post by mnholdem on Jul 25, 2018 10:23:44 GMT -5
More publications are coming, IMO. Awareness will grow among endocrinologists, primary care physicians and other diabetes healthcare professionals.
|
|
|
|
Post by mnholdem on Jul 25, 2018 6:10:05 GMT -5
Satellite dish picking up U.S. commercials is most likely the reason IMO. I didn’t intend to suggest that the 2nd term sheet involves Canada but it is another market I hope is being considered. My guess is that the term sheet involves China and the delay involves Amphastar Pharma and their purchase agreement with MannKind which grants them first rights to sales of Afrezza in that country. I think that AMPH may team up with a Chinese medical sales company and that it’s possible may manufacture Afrezza. Amphastar does specialize in manufacturing inhalants and difficult to produce generics.
There is a mandatory timeline on the First Right provision in the Agreement so one might be able to estimate a date of agreement, assuming the Amphastar has exercised it’s right to match other partnership offers.
|
|
